RE:New 52-week high for S&P Biotech ETFLast time the S&P Biotech ETF was trading at this level looks about April 4, 2022 judging by the Stockhouse chart. AEZS was US$9.34 or about 400% higher. It's a different situation now but when AEZS announces its clinical pediatric data and a diagnostic deal(s) as well as potential clinical trial 'go' decisions for its pipeline(eg. AIM Biologicals) and the clinical path forward it could get interesting. H.C. Wainwright's US$15 target price for AEZS was set around the bottom of the bioteh market before the recent surge. Getting this merger uncertainty out of the way and some analyst coverage can help immeasurably detailing this opportunity to the street.
prophetoffactz wrote: 96.18+1.43 (+1.51%) As of 09:35AM EST. Market open.
Up 50% in four months.
Gilles did his part to scoop biotech assets up below cash after the worst biotech bear market in history. We may now be on the cusp of a multi-year breakout.